Investor Presentaiton
CTS Key Business Updates (Cont'd)
Regulatory Affairs ("RA")
As of June 30, 2023, we have a total of 940 accumulated RA project experience
In the first half of 2023, we also added 18 new U.S. Food and Drug Administration (“FDA IND”) projects, of which 9 of them have successfully filed
and were cleared for clinical trial
In the first half of 2023, we assisted 7 products to be registered and approved in China, as well as assisted with 16 Investigational New Drug
("IND")/ MRCT clinical trial filings in multiple countries
The number of customers increase to 700 as of June 30, 2023, from 649 as of December 31, 2022
Medical Device & IVD
As of June 30, 2023, our medical device team has served more than 1,700 global clients, accumulated experience over more than 5,700 medical
device and IVD project registration projects, and more than 700 medical device and IVD clinical trials
We offer an integrated service that covers the full lifecycle of medical device R&D, providing services that cover product development strategy,
pre-clinical trial, clinical trial, registration, and post-market
Rewarded as "Best Medical Device Overseas Enabling Service Provider of 2023"(1)
● Tigermed (1) Awarded by China-Go-Global Medical Device Conference
14View entire presentation